Zacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.05 EPS

Equities analysts expect that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report earnings of $0.05 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Enanta Pharmaceuticals’ earnings, with estimates ranging from ($0.04) to $0.13. Enanta Pharmaceuticals reported earnings per share of ($0.26) during the same quarter last year, which indicates a positive year-over-year growth rate of 119.2%. The business is scheduled to announce its next earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of ($1.57) per share for the current year, with EPS estimates ranging from ($2.36) to ($0.78). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business had revenue of $75.93 million during the quarter, compared to the consensus estimate of $73.80 million. During the same period last year, the business posted ($0.09) earnings per share. The business’s revenue was up 491.3% on a year-over-year basis.

A number of analysts recently commented on ENTA shares. Robert W. Baird boosted their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $54.00 target price on shares of Enanta Pharmaceuticals in a research report on Friday, October 20th. BidaskClub upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 11th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $38.00 price target (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $46.25.

A number of hedge funds have recently added to or reduced their stakes in ENTA. Parametric Portfolio Associates LLC boosted its stake in Enanta Pharmaceuticals by 20.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 11,854 shares of the biotechnology company’s stock valued at $365,000 after purchasing an additional 1,989 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Enanta Pharmaceuticals by 2.9% in the 1st quarter. Teachers Advisors LLC now owns 25,182 shares of the biotechnology company’s stock worth $776,000 after buying an additional 700 shares during the last quarter. Thrivent Financial For Lutherans boosted its stake in shares of Enanta Pharmaceuticals by 5.1% in the 1st quarter. Thrivent Financial For Lutherans now owns 7,840 shares of the biotechnology company’s stock worth $241,000 after buying an additional 380 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 7.2% in the 1st quarter. Vanguard Group Inc. now owns 792,165 shares of the biotechnology company’s stock worth $24,399,000 after buying an additional 53,007 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Enanta Pharmaceuticals by 129.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after buying an additional 233,265 shares during the last quarter. Institutional investors and hedge funds own 66.45% of the company’s stock.

Enanta Pharmaceuticals (NASDAQ:ENTA) opened at $47.86 on Friday. Enanta Pharmaceuticals has a 12-month low of $25.92 and a 12-month high of $50.92. The firm has a market capitalization of $913.65, a PE ratio of 54.39 and a beta of 0.66.

WARNING: “Zacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.05 EPS” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/zacks-analysts-expect-enanta-pharmaceuticals-inc-enta-to-post-0-05-eps.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply